ARCHIVES

FDA will return memento given to McClellan by NCI Director Andrew von Eschenbach.

This article is from The Cancer Letter archive.

Vol. 30 No. 06 | February 6, 2004

Download PDF Visit The Full Archive

Related Articles

Chemoprevention Clinical Trial RFA Being Developed For January Concept Review, Along With “Bridge” RFA

November 27, 1981

In Multi-Site Phase I Studies, No Investigator Sees All Toxicities

March 26, 2010

FDA Forms Office of Combination Products;

January 10, 2003

Phase III Alimta Trial Fails To Extend Progression-Free Survival Without Grade 4 Adverse Events

June 28, 2013

DCT Board Okays New Projects, Rejects Nutrition Research Proposal

October 27, 1978

NCI To Recomplete CIDAC Contracts

September 23, 1977